Physician profile
Kai Chin
NPI 1427469402
$1,850.82
in general payments reported to CMS, 2019-2025
28 companies · $842 in 2025
The $842 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $8.49 · 2023: $249 · 2024: $751 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,830 · Education: $12.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,830.01 |
| Education | $12.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $156.25 | 2023-2025 | Impella |
| Travere Therapeutics, INC. | $147.64 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $145.74 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.00 | 2024 | Jardiance |
| Amgen INC. | $126.64 | 2024-2025 | Krystexxa, Tavneos |
| Calliditas Therapeutics US INC. | $120.64 | 2024-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $112.26 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $97.57 | 2024-2025 | Dupixent |
| Otsuka America Pharmaceutical, INC. | $84.78 | 2023-2024 | Jynarque |
| Novo Nordisk INC | $77.62 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Aurinia Pharma U.S., INC. | $67.21 | 2024-2025 | Lupkynis |
| Scpharmaceuticals INC. | $62.56 | 2024-2025 | |
| Ardelyx, INC. | $61.56 | 2023-2025 | Ibsrela |
| Avadel Cns Pharmaceuticals, LLC | $58.40 | 2025 | Lumryz |
| Astrazeneca Pharmaceuticals Lp | $51.23 | 2023-2025 | Farxiga |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $46.07 | 2025 | |
| Verona Pharma, INC. | $40.67 | 2025 | Ohtuvayre |
| Pfizer INC. | $38.33 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $36.06 | 2025 | Empaveli |
| Outset Medical INC | $35.78 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.28 | 2024 | Glassia |
| Vifor Pharma, INC. | $29.68 | 2024-2025 | Zemaira |
| Tactile Systems Technology INC | $24.96 | 2025 | Nimbl, Flexitouch Plus |
| United Therapeutics Corporation | $15.38 | 2025 | Tyvaso |
| Corcept Therapeutics | $14.57 | 2024 | Korlym |
| Baxter Healthcare | $14.23 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Glaxosmithkline, LLC. | $14.22 | 2025 | Benlysta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $8.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kai Chin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.